MNG522
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.419
- WNT_BETA_CATENIN_SIGNALING+0.334
- MITOTIC_SPINDLE+0.312
- UV_RESPONSE_DN+0.211
- HEDGEHOG_SIGNALING+0.192
- HEME_METABOLISM+0.162
- PROTEIN_SECRETION+0.133
- PEROXISOME+0.106
- G2M_CHECKPOINT+0.104
- TGF_BETA_SIGNALING+0.092
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.473
- IL6_JAK_STAT3_SIGNALING-0.426
- INFLAMMATORY_RESPONSE-0.412
- HYPOXIA-0.408
- ALLOGRAFT_REJECTION-0.390
- P53_PATHWAY-0.386
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.348
- OXIDATIVE_PHOSPHORYLATION-0.340
- INTERFERON_GAMMA_RESPONSE-0.336
- INTERFERON_ALPHA_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG420 | — | — | 0.902 |
| 2 | 7C225672-8372-4202-A749-3D8E9A0747CC | — | — | 0.841 |
| 3 | 8cace84b-8d01-46cf-8b59-9f1e53249863 | — | — | 0.827 |
| 4 | 70002 | EPN | Supratentorial EPN | 0.827 |
| 5 | MNG920 | — | — | 0.823 |
| 6 | TCGA-A8-A091-01A-11R-A00Z-07 | — | B | 0.816 |
| 7 | 959c268c-637f-4f39-a254-a505c57e8448 | — | — | 0.806 |
| 8 | BSR_16_0051_A2_S82 | — | A | 0.805 |
| 9 | MDT-AP-3325 | Med | Medulloblastoma | 0.796 |
| 10 | SRR9879267 | — | cohortA1 | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.419 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.334 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.312 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.211 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.192 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.162 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.133 | Remibrutinib | — uncovered |
| PEROXISOME | 0.106 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.104 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.092 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.072 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.063 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.059 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.054 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.045 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.023 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.013 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.005 | Inavolisib | — uncovered |